While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
A business making money today isn’t necessarily a winner, which is why we analyze companies across multiple dimensions at StockStory. That said, here are three profitable companies that don’t make the cut and some better opportunities instead.
Red Rock Resorts (RRR)
Trailing 12-Month GAAP Operating Margin: 29.3%
Founded in 1976, Red Rock Resorts (NASDAQ: RRR) operates a range of casino resorts and entertainment properties, primarily in the Las Vegas metropolitan area.
Why Do We Think RRR Will Underperform?
- Lackluster 1.7% annual revenue growth over the last five years indicates the company is losing ground to competitors
- Demand is forecasted to shrink as its estimated sales for the next 12 months are flat
- Eroding returns on capital suggest its historical profit centers are aging
At $54.72 per share, Red Rock Resorts trades at 33.4x forward P/E. Read our free research report to see why you should think twice about including RRR in your portfolio.
CooperCompanies (COO)
Trailing 12-Month GAAP Operating Margin: 19%
With a history dating back to 1958 and a portfolio spanning two distinct healthcare segments, Cooper Companies (NASDAQ: COO) develops and manufactures medical devices focused on vision care through contact lenses and women's health including fertility products and services.
Why Does COO Worry Us?
- Free cash flow margin shrank by 6.4 percentage points over the last five years, suggesting the company is consuming more capital to stay competitive
- Low returns on capital reflect management’s struggle to allocate funds effectively
CooperCompanies is trading at $72.75 per share, or 17.5x forward P/E. Check out our free in-depth research report to learn more about why COO doesn’t pass our bar.
West Pharmaceutical Services (WST)
Trailing 12-Month GAAP Operating Margin: 19.1%
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Does WST Fall Short?
- Sales stagnated over the last two years and signal the need for new growth strategies
- Day-to-day expenses have swelled relative to revenue over the last two years as its adjusted operating margin fell by 5.7 percentage points
- Diminishing returns on capital suggest its earlier profit pools are drying up
West Pharmaceutical Services’s stock price of $222.26 implies a valuation ratio of 34.8x forward P/E. If you’re considering WST for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
